A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers

Trial Profile

A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) After Neoadjuvant Chemotherapy in Women With HER2/Neu (0-2+), Hormone Receptor (HR) Negative Stage II-III Breast Cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2016

At a glance

  • Drugs Anti-CD3-anti-HER2-activated T-cells (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2016 Status changed from suspended to active, no longer recruiting.
    • 18 Feb 2016 Status changed from recruiting to suspended, according to ClinicalTrials.gov record.
    • 21 Aug 2015 Planned End Date changed from 1 Jun 2015 to 1 Apr 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top